Amongst all developed c-MET inhibitors Pha665752, a potent ATP-competitive agent, was shown to exhibit the highest potential for radiosensitization in nasopharyngeal cancer cell lines. The gene discussed is MET; the disease is nasopharyngeal carcinoma.